Search Results
Your search for ,NOt matches 22378 pages
Showing 13951 - 14000Effect of Fixed Second Appointments on Breast Cancer Screening Attendance
In a UK study reported in The Lancet Oncology, Allgood et al found that provision of a second timed appointment for breast cancer screening improved screening rates among women who did not attend a first offered appointment. Study Details In the study, women who were invited for breast screening...
AKT Inhibitor Activity in AKT1-Mutant Solid Tumors
As reported by Hyman et al in the Journal of Clinical Oncology, a basket study has shown activity of an investigational ATP-competitive pan-AKT kinase inhibitor (AZD5363) in solid tumors with AKT1 E17K mutation. Study Details In the study, 52 patients with advanced estrogen...
Common Causes of Death Predominate Among Long-Term Colorectal Cancer Survivors
Patients with colorectal cancer who survive at least 5 years are increasingly likely to die from causes that are common in the general population, highlighting the importance of screening and lifestyle modification, suggested a large cohort study conducted in California.1 The analysis of more than...
New Immunotherapy Combinations Gain Ground in Advanced Melanoma, but Results Preliminary
Attention is focused among the cancer community on identifying the optimal immunotherapy combinations, with more than 800 ongoing trials of combination therapy. Two studies presented at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) reported promising preliminary...
Expert Point of View: David L. Porter, MD & Jonathan S. Serody, MD
In a separate interview with The ASCO Post, David L. Porter, MD, Director of Blood and Marrow Transplantation and the Jodi Fisher Horowitz Professor in Leukemia Care Excellence at the University of Pennsylvania, Philadelphia, said: “It is encouraging that many patients with acute lymphoblastic...
CAR T Cells in Relapsed B-Cell Acute Lymphoblastic Leukemia
Updated results in 51 adults with relapsed B-cell acute lymphoblastic leukemia (ALL) treated with chimeric antigen receptor (CAR) T cells at Memorial Sloan Kettering Cancer Center in New York showed high complete response rates regardless of pre–CAR T disease burden.1 That said, pretreatment...
Marie Bleakley, MD, PhD, Receives Research Grant in Immuno-oncology From Stand Up To Cancer
Marie Bleakley, MD, PhD, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center (Fred Hutch), has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer (SU2C). Dr. Bleakley will use the 3-year, $750,000 award to develop T-cell therapies...
Alice T. Shaw, MD, PhD, Joins LUNGevity Foundation Scientific Advisory Board
LUNGevity Foundation has announced that Alice T. Shaw, MD, PhD, joined its Scientific Advisory Board, a group of 20 world-renowned scientists and researchers who guide LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and...
Metastatic Urothelial Carcinoma: A Model Malignancy for Immune Checkpoint Blockade
Platinum-based combination chemotherapy became a mainstay of first-line treatment for metastatic urothelial cancer in the 1980s. With combination platinum-based regimens, 40% to 50% of patients achieve an objective response to treatment. However, aside from approximately 5% to 10% of patients who...
CheckMate 275 Supports FDA Approval of Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy
As reported in The Lancet Oncology by Padmanee Sharma, MD, PhD, of MD Anderson Cancer Center, and colleagues, the phase II CheckMate 275 trial has shown that nivolumab (Opdivo) produced durable responses in patients with metastatic urothelial cancer who had received at least one prior...
Expert Point of View: Aditya Bardia, MD, MPH
Commenting on the phase I study of atezolizumab (Tecentriq) presented at the 2017 American Association for Cancer Research Annual Meeting, Aditya Bardia, MD, MPH, Attending Physician at Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, said: “It is very encouraging to...
The Ongoing Challenges of Lung Cancer Screening
Lung cancer persistently remains the leading cause of cancer death among men and women in the United States. Only about 15% of lung cancers are diagnosed at the localized stage, when clinical intervention could markedly improve patient outcomes. For decades, lung cancer specialists and advocacy...
Atezolizumab Improves Overall Survival in Small Subset of Patients With Triple‑Negative Breast Cancer
Triple-negative breast cancer is an aggressive disease with no approved targeted therapy, and it remains challenging to treat. Early data from a phase I study suggest that the PD-L1 inhibitor atezolizumab (Tecentriq) can extend the lives of a subset of women who respond to this checkpoint...
FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site-Agnostic Indication
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...
Abemaciclib Active in Metastatic Breast Cancer
In the single-arm phase II MONARCH 1 trial, the investigational cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib achieved an objective response in about 20% of heavily pretreated patients with metastatic hormone receptor–positive, HER2-negative breast cancer and a disease control rate of...
Anticipate Sexual Dysfunction in Patients on Aromatase Inhibitors
For patients with breast cancer starting on aromatase inhibitors, sexual dysfunction is commonly reported. Early intervention may lessen its impact—but it’s not an easy fix, says a specialist in this area, Leslie R. Schover, PhD. Dr. Schover is Founder of Will2Love, an online sexual health program ...
Key Gene Controlling Tumor Growth in Gliomas Pinpointed
Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and may strongly influence survival rates of patients. The findings, published by Edwards et al in Scientific Reports,1 may move physicians closer to their goal of better...
Expert Point of View: Julie Margenthaler, MD
“This study of 2,759 patients with ductal carcinoma in situ provides data for women who are considering their surgical options,” said Julie Margenthaler, MD, a breast surgeon at Washington University of Medicine, St. Louis, and Communications Chair of the American Society of Breast Surgeons...
Study Establishes Low Risk for Contralateral Breast Cancer After Diagnosis of Ductal Carcinoma in Situ
An increasing number of women with ductal carcinoma in situ are undergoing contralateral mastectomy, but the 5-year risk of cancer in the opposite breast is only about 3%, a study from Memorial Sloan Kettering Cancer Center recently found.1 Investigators hope these numbers will dissuade women from ...
Optimizing Treatment for Elderly Patients With Glioblastoma
In 2005, Stupp and colleagues published their landmark paper demonstrating in a randomized phase III trial that the addition of temozolomide to radiation increased overall survival in patients with newly diagnosed glioblastoma. Notably, patients over age 70 years were excluded from this study.1...
Short-Course Radiotherapy Plus Temozolomide Improves Survival in Older Patients With Glioblastoma
In a phase III trial reported in The New England Journal of Medicine, James R. Perry, MD, of Sunnybrook Health Sciences Centre, Toronto, and colleagues found that adding temozolomide to short-course radiotherapy improved overall survival in patients aged at least 65 years with newly diagnosed...
Managing Small Renal Masses: A Point-by-Point Consideration of ASCO’s Clinical Practice Guideline
As reviewed in this issue of The ASCO Post, a recent issue of the Journal of Clinical Oncology featured an ASCO Clinical Practice Guideline on the management of small renal masses reported by Finelli and colleagues.1 This comprehensive guideline is written by a group of well-regarded and...
Triple‑Modality Therapy Achieves Good Control in Inflammatory Breast Cancer
Contemporary triple-modality therapy achieves excellent locoregional tumor control of inflammatory breast cancer, with only 4 locoregional recurrences out of 114 patients treated at The University of Texas MD Anderson Cancer Center, Houston. The investigators described their approach at the...
ASCO Clinical Practice Guideline: Management of Small Renal Masses
As reported in the Journal of Clinical Oncology by Antonio Finelli, MD, of Princess Margaret Cancer Center, Toronto, and colleagues, ASCO has released a clinical practice guideline on management of small renal masses.1 The guideline was derived from an expert panel literature search for and...
Revisions to the International Neuroblastoma Response Criteria
A consensus statement from a National Cancer Institute–sponsored clinical trials planning meeting, reported in the Journal of Clinical Oncology by Park et al, presents revisions to the International Neuroblastoma Response Criteria (INRC) for assessing treatment response in patients with...
Outcomes in Patients With Double-Hit Lymphoma After First Complete Remission
In an analysis reported in the Journal of Clinical Oncology, Landsburg et al found no significant benefit of consolidative autologous stem cell transplantation in patients with double-hit lymphoma after first complete remission. They also found evidence of poorer outcome with front-line R-CHOP...
Intratumoral Plasmid Interleukin-12 Boosts Response to Pembrolizumab
In patients with stage III/IV melanoma, immunologically “cold” tumors were rendered immunologically active through intratumoral injections of plasmid interleukin-12 (IL-12) combined with pembrolizumab (Keytruda).1 Describing the approach at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium,...
ASCO Provisional Clinical Opinion on Hormonal Therapy for Castration-Resistant Prostate Cancer
On April 25, ASCO issued a provisional clinical opinion on the use of second-line hormonal therapy for men with castration-resistant prostate cancer who have not yet received chemotherapy. The recommendations of this provisional clinical opinion were informed by evidence from a systematic review of ...
Accrual of Older Patients to Breast Cancer Trials: A Critical Need
As the U.S. population ages,1 the number of older women with breast cancer will increase,2 as well as the number of patients with frailty and other comorbid medical conditions. These patients are at increased risk for toxicity and functional decline during their breast cancer treatment course....
Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology by Allison W. Kurian, MD, of Stanford University School of Medicine, and colleagues, surveys in a population-based sample of patients recently diagnosed with breast cancer indicate that many undergo genetic risk testing without seeing a genetics...
Rates of Oral HPV Infection Plummet After Vaccination
Vaccination against the human papillomavirus (HPV) reduced the risk of acquiring oral HPV infections by 88%, in one of the first large studies to explore vaccination’s impact in the oropharynx. The study will be presented at the 2017 ASCO Annual Meeting, and the findings were released in advance of ...
Provision of Genetic Services to Women With Breast Cancer: We Must Do Much Better
Genetic testing for inherited cancer susceptibility is increasingly part of the care of cancer patients and their relatives. Early clinical guidelines recommended BRCA1/2 testing for women diagnosed with breast or ovarian cancer if they also have a significant family cancer history or Ashkenazi...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...
Suboptimal Genetic Testing and Counseling Among Women With Newly Diagnosed Breast Cancer
In a population-based study reported in a research letter in JAMA, Allison W. Kurian, MD, of Stanford University School of Medicine, and colleagues found that genetic testing and genetic counseling are suboptimal among women with newly diagnosed breast cancer.1 Study Details The study involved...
Leader in International Clinical Trials, Robert L. Comis, MD, FASCO, Dies at 71
Robert L. Comis, MD, FASCO, Co-Chair of the ECOG-ACRIN Cancer Research Group, succumbed to a sudden illness at his home and died on May 10, 2017, at the age of 71. A giant in national and international clinical research since 1977, Dr. Comis is known as a champion of patient access to cancer...
Pediatric Oncology Patient and Parent Attitudes on Early Palliative Care Integration
Few pediatric oncology patients or their parents expressed negative attitudes toward early integration of palliative care during cancer treatment, in a study by Deena R. Levine, MD, of the Division of Quality of Life and Palliative Care, St Jude Children’s Research Hospital, and colleagues reported ...
Immunotherapy Clinical Trials in Metastatic Melanoma
A Danish study reported in the European Journal of Cancer by Marco Donia, MD, PhD, of the Center for Cancer Immune Therapy, Herlev Hospital, Denmark, and colleagues indicates that more than half of patients with metastatic melanoma do not satisfy requirements for enrollment in phase III trials of...
ASCO CEO Reflects on His First Year in Office and What Is Ahead
June 27, 2017, marks the 1-year anniversary since Clifford A. Hudis, MD, FACP, FASCO, began his tenure as Chief Executive Officer of ASCO. With the launch of the national Cancer Moonshot and the changes in the White House and Congress, it has been a year of tremendous activity drawing on all of...
The Role of Meditation in Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, present the case...
Expect Questions From Patients Who ‘Do Everything Right’ but Still Develop Cancer
A study reported in Science found that more than two-thirds of human cancers are caused by random mutations made during DNA replication.1 “The main message we would like to convey is that even for many patients who follow all of the guidelines from the advisory bodies—they don’t smoke, exercise...
Recognizing Major Role of Random Mutations in Causing Cancer Does Not Diminish Importance of Primary Prevention
Random mistakes made during DNA replication are responsible for about two-thirds of the mutations that cause human cancers, according to a study reported in Science.1 Recognizing the role of these replication errors “does not diminish the importance of primary prevention but emphasizes that not all ...
Expert Point of View: Lipika Goyal, MD
Commenting on the BILCAP study, Lipika Goyal, MD, an oncologist at Massachusetts General Hospital, Boston, said: “These results are very intriguing. There is no current standard of care for adjuvant therapy of biliary tract cancer. Our high-risk patients [ie, patients with node-positive disease,...
Adjuvant Capecitabine for Biliary Tract Cancer Yields Significant Improvement in Overall Survival
There is no standard adjuvant therapy for patients with resectable biliary tract cancer, but that may be about to change based on results of the phase III BILCAP trial.1 Adjuvant capecitabine significantly improved overall survival in the BILCAP trial, and this is the first study to show a benefit...
My Year of Living Wonderfully: 12 Months as ASCO President
EACH YEAR, the ASCO President chooses a theme for his or her term, which is not a trivial pursuit. Trying to think up something novel and catchy, yet not schmaltzy, is quite a challenge. However, in my year as Chair of the Scientific Program Committee for the 2010 ASCO Annual Meeting, then during...
Lung Cancer: Hope From Science
The following essay by Paul A. Bunn, Jr, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I grew up in ...
‘It Is What It Is’
Mark looked at me shyly through his oversized Elvis Costello–style glasses. Was he feeling embarrassed by his own reply or just waiting for my reaction? He was sitting between his mom and dad, wearing a t-shirt with a huge Minion print. His braces showed when he smiled, something he does often in...
Are Oncologists Discussing Exercise With Patients?
It is well documented that physical activity benefits patients with cancer, both during and after treatment. Exercise helps patients combat both the physical and psychological impacts of cancer treatment, giving them a sense of well-being, control, stress reduction, and empowerment. However,...
RECIL 2017: New Response Evaluation Criteria in Lymphoma Clinical Trials
New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the Response Evaluation Criteria in Solid Tumors (RECIST). The new criteria were reported by Younes et al in Annals ...
Alcohol Consumption May Be Associated With Higher Risk of Breast Cancer in African American Women
Alcohol intake was associated with an increased risk of breast cancer in a large study of African American women, indicating that they, like white women, may benefit from limiting their alcohol consumption, according to results of a study published by Williams et al in Cancer Epidemiology,...
AUA 2017: Phase III Study of Blue Light Cystoscopy With Optical Imaging Agent in Bladder Cancer
New phase III study results of blue light flexible cystoscopy (BLFC) with an optical imaging agent (Hexvix/Cysview) were presented by Daneshmand et al during a late-breaking plenary session at the 2017 American Urological Association (AUA) Annual Meeting (Abstract PPTLBA-02). Major Findings The...
